Context Therapeutics(CNTX.US)

Last Updated 19:00:00 ET
longbridge loading

Context Therapeutics Decline Means Insider Profits Down To US$237k

Simplywall·
US
CNTX
+7.62%
US
XBI
+0.81%
US
LABU
+2.48%
Simplywall·
US
CNTX
+7.62%
US
XBI
+0.81%
US
LABU
+2.48%

Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

TradingView·
US
BCAB
-0.14%
US
CNTX
+7.62%
TradingView·
US
BCAB
-0.14%
US
CNTX
+7.62%

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

StockTitan·
US
CNTX
+7.62%
US
BCAB
-0.14%
StockTitan·
US
CNTX
+7.62%
US
BCAB
-0.14%

What is HC Wainwright's Estimate for CNTX FY2030 Earnings?

Market Beat·
US
CNTX
+7.62%
US
XBI
+0.81%
US
LABU
+2.48%
Market Beat·
US
CNTX
+7.62%
US
XBI
+0.81%
US
LABU
+2.48%

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | CNTX Stock News

StockTitan·
US
CNTX
+7.62%
US
PBE
+0.35%
US
ARKG
+3.35%
StockTitan·
US
CNTX
+7.62%
US
PBE
+0.35%
US
ARKG
+3.35%

JonesTrading Remains a Buy on Context Therapeutics (CNTX)

Tip Ranks·
US
LABU
+2.48%
US
CNTX
+7.62%
US
SBIO
+1.84%
Tip Ranks·
US
LABU
+2.48%
US
CNTX
+7.62%
US
SBIO
+1.84%
© 2026 Longbridge｜Disclaimer